MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study

অনুরূপ উপাদানগুলি

• MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly
  অনুযায়ী: Samson, Susan Leanne, অন্যান্য
  প্রকাশিত: (2020)
• MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
  অনুযায়ী: Nachtigall, Lisa B, অন্যান্য
  প্রকাশিত: (2020)
• MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study
  অনুযায়ী: Samson, Susan Leanne, অন্যান্য
  প্রকাশিত: (2020)
• MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study
  অনুযায়ী: Fleseriu, Maria, অন্যান্য
  প্রকাশিত: (2020)
• MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
  অনুযায়ী: Labadzhyan, Artak, অন্যান্য
  প্রকাশিত: (2020)